ORKA

Oruka Therapeutics, Inc.

Oruka Therapeutics, Inc. (ORKA) has 20 SEC Form 4 filings (86 transaction rows) in the rolling window, disclosed by 7 distinct insiders. Most recent filing: Jul 15, 2026.

The most active filer is Chief Medical Officer Goncalves Joana with 7 filings. Insiders have net sold $314.5M over the trailing 6 months.

  • Industry:Biotechnology
  • CEO:Lawrence Otto Klein
  • Employees:68
  • HQ:Menlo Park, CA, US
  • IPO:1997-08-08

Insider Buying

$0

reported purchases (SEC code P)

Insider Selling

$315.1M

reported sales (SEC code S)

Unique Insiders

7

in the rolling window

Market Cap

$5.3B

latest known value

Source
Sale$604KJul 15SEC ↗
Sale$846KJul 13SEC ↗
Sale$300.0MJul 2SEC ↗
Sale$472KJul 1SEC ↗
Sale$128KJun 22SEC ↗
Sale$660KJun 15SEC ↗
Sale$28KJun 15SEC ↗
Sale$551KJun 15SEC ↗
Sale$120KJun 15SEC ↗
Sale$42KJun 15SEC ↗
Quinlan Paul TFirst filing
Sale$51KJun 15SEC ↗
Sale$1.6MJun 12SEC ↗
Sale$882KJun 12SEC ↗
Dambkowski CarlFirst filing
Sale$6.2MMay 22SEC ↗
Agarwal ArjunFirst filing
Sale$608KMay 18SEC ↗
Sale$433KMay 16SEC ↗
Sandler Laura LeeFirst in 4 months
Sale$319KMay 1SEC ↗
Sale$463KApr 15SEC ↗
Sale$313KMar 17SEC ↗
Sale$227KFeb 17SEC ↗
Sandler Laura LeeFirst filing
Sale$371KJan 2SEC ↗
Goncalves JoanaFirst filing
Sale$214KDec 19SEC ↗

Related companies

Oruka Therapeutics, Inc. is in the Healthcare sector.